trending Market Intelligence /marketintelligence/en/news-insights/trending/nOgXAdrdMf6SbzH5loSVXA2 content esgSubNav
In This List

Evolent Health updates FY'17 guidance

Blog

Fintech Intelligence Digital Newsletter: May 2021

Street Talk – Episode 76: Record pace of fintech M&A, funding in Q1'21 has legs

Fintech Intelligence Digital Newsletter: April 2021

Podcast

Street Talk | Episode 76: Record pace of fintech M&A, funding in Q1'21 has legs


Evolent Health updates FY'17 guidance

Evolent Health Inc. has updated its guidance for the full year 2017.

The company now expects adjusted revenue to be in the range of $424.0 million to $428.0 million, up from previous guidance of a range of $415.0 million to $425.0 million. Evolent Health narrowed its full-year adjusted EBITDA to a range of a loss of $8.0 million to a loss of $4.0 million, compared with previous guidance of a loss of $8.0 million to a breakeven.

Third-quarter adjusted revenue is expected to be in the range of $103.0 million to $105.0 million, and adjusted EBITDA is expected to break even.

The company reported a second-quarter loss available to common shareholders of $16.9 million, or a loss of 28 cents per common share, compared to a loss of $8.4 million, or a loss of 20 cents per common share, in the same period of 2016.

The S&P Capital IQ consensus GAAP estimate for the second quarter called for a loss of 27 cents per share.